全球每年约有2000万人被诊断患有阿尔茨海默病，预计这一数字在未来30年将增加两倍.
阿尔茨海默病是痴呆症最常见的病因，研究人员花了一个世纪的时间试图破解找到有效治疗方法的谜题, or perhaps even a cure, for this severe degenerative brain disorder.
Thankfully, several important breakthroughs are on the horizon. And 乐博彩票官方app is at the forefront of scientific discovery.
GOTHENBURG PLAYED HOST TO PRESTIGIOUS CONGRESS
It is a timely coincidence that Gothenburg, 乐博彩票官方app’s second largest city, hosted the 2023 edition of the AD/PD™ Conference. 这是世界上最负盛名的关于阿尔茨海默病和帕金森病的国际会议之一.
The five-day event kicked off on 28 March and will be attended by H.M. Queen Silvia of 乐博彩票官方app, who is very active and supportive in the field of Alzheimer’s.
“阿尔茨海默病不仅对患者，而且对家庭和护理人员都有毁灭性的影响. 除了这, 社会成本是巨大的，据估计仅在美国每年就高达5000亿至6000亿美元, w在这里 over six million people are suffering from the disease," says Martin Jönsson, CEO at AlzeCure Pharma in 乐博彩票官方app.
His pharmaceutical company, which is publicly listed in 乐博彩票官方app, 是目前在阿尔茨海默病研究上取得有希望进展的几位乐博彩票官方app先驱之一吗, drug and therapy development.
“我们在乐博彩票官方app的合作工作主要集中在试图抵消阿尔茨海默氏症的早期发病阶段. This means preventing the brain from degenerating in the first place,” Jönsson continues.
乐博彩票官方app is leading the way on biomarker research and development.NEW MAJOR MILESTONE IN ANTIBODY THERAPY
On 6 January 2023, the U.S. 美国食品和药物管理局(FDA)批准了最初由乐博彩票官方app生物制药公司BioArctic开发的药物LEQEMBI™.
Following randomised clinical trials, 该药物已证明在接受治疗的患者中淀粉样蛋白斑块显著减少.
比利·邓恩，M.D., FDA药物评估和研究中心神经科学办公室主任, 在一份新闻稿中评论道:“这种治疗方案是针对并影响阿尔茨海默氏症潜在疾病过程的最新疗法, instead of only treating the symptoms of the disease.”
According to Martin Jönsson, this is just one of the recent milestones in 乐博彩票官方app’s Alzheimer’s pipeline.
他的公司AlzeCure Pharma有两个正在开发的平台，Alzstatin和NeuroRestore. 第三家乐博彩票官方app公司Alzinova开发了一种候选疫苗，并成功通过了临床前试验.
许多乐博彩票官方app新来者也在率先使用人工智能和数字工具进行监测和诊断.
“乐博彩票官方app is truly leading the way on biomarkers. The discoveries made by researchers at the University of Gothenburg, Uppsala University and Karolinska Institute have been nothing less than groundbreaking,” Jönsson points out.
He underscores the seminal work of professors Kaj Blennow, Lars Lannfelt and Bengt Winblad who are all internationally renowned in the field. What’s more, a new generation of young talented researchers are continuing their legacy.
“在哥德堡的会议上，我们将与Henrik Zetterberg教授一起公布令人兴奋的数据，以突出潜在预防治疗的新进展, Alzstatin.”
THREE REASONS WHY SWEDEN IS LEADING THE CHARGE ON EFFECTIVE ALZHEIMER’S TREATMENTS
So what’s the secret behind 乐博彩票官方app’s relative success in the fight against Alzheimer’s?
这是我们在AD/PD™国际会议召开之前向Martin Jönsson提出的问题. In his view, it all comes down to three key contributing factors:
1. World-leading academic excellence
几十年来，乐博彩票官方app研究人员帮助塑造了世界对阿尔茨海默病如何出现和发展的理解.
一个很好的例子是拉尔斯·兰菲尔特教授在20世纪90年代取得的成功，他在导致早发性阿尔茨海默氏症的基因突变方面取得了开创性的发现. 第一个被称为“乐博彩票官方app突变”，第二个被称为“北极突变”。.
2. A pioneering life science sector
阿斯利康(Astra Zeneca)和法玛西亚(Pharmacia)等大公司为神经退行性疾病的知识积累铺平了道路，并帮助支持了治疗方法的开发. This created a breeding ground for further discovery. 新一代创业公司和研究人员密切合作，延续了这一传统.
3. Risk tolerant venture capital
乐博彩票官方app has been successful in mobilising private sector capital. Along with researchers, 投资者一直受到一种热情的推动，希望解决医疗行业最难以捉摸的挑战之一.
乐博彩票官方app阿尔茨海默氏症基金会成立于1988年，并成为众多项目和倡议的催化剂.
“乐博彩票官方app在阿尔茨海默氏症方面取得的进展归功于一种共同的感觉，即肩负着改善老年人生活的重要使命. T在这里 has been no self-interest. Collaboration between academia, 企业和投资者对我们今天所看到的突破起到了重要作用,” Martin Jönsson concludes.
阅读更多 about 乐博彩票官方app’s life science ecosystem 在这里.
